Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen to Provide Real-Time PCR Services Based on Exiqon's miRNA Assay Product

Premium

Exiqon and Asuragen said this week that they have signed a service center agreement that allows Asuragen to provide real-time PCR services based on Exiqon's MiRcury LNA Universal RT microRNA PCR products.

Asuragen's genomic services division provides a comprehensive range of nucleic acid-based services from biomarker discovery to development of companion diagnostics, including isolation and preparation from multiple sample types, genomic profiling, miRNA/mRNA expression profiling, assay development and validation, CLIA-based clinical trial testing, bioinformatics, and regulatory services.

Exiqon's LNA-based microRNA real-time PCR profiling combines a Universal RT reaction with locked nucleic acid-enhanced PCR primers, which results in a high degree of sensitivity and specificity for all sample types, the company said. The assay system "holds great promise as a non-invasive way to discover important new biomarkers for a wide range of diseases and biological processes," Exiqon said.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.